Application of afatinib combined with np regimen in the treatment of stage iv non-small cell lung cancer and its effect on patient survival.

Abstract

To explore the application of afatinib combined with NP regimen in the treatment of stage IV non-small cell lung cancer and its effect on patient survival, the data of 100 patients with stage IV non-small cell lung cancer admitted to our hospital from February 2017 to February 2018 were retrospectively analyzed. They were equally divided into observation group and control group, with 50 in each group. The control group was treated with an NP regimen and the observation group was treated with afatinib. The disease control rate (DCR) of the observation group was remarkably higher than that of the control group (P<0.05). The observation group witnessed a markedly higher clinical benefit rate relative to the control group (P<0.05). A remarkably longer median treatment failure time of the observation group was observed as compared to the control group (P<0.001). There was no statistical difference in the incidence of adverse reactions between the observation group and the control group (P>0.05). Afatinib combined with NP regimen treatment increases the clinical benefit rate of patients with stage IV non-small cell lung cancer, improves its short-term efficacy and helps prolong the survival time of patients, with excellent safety profile.

• Authors: Fang Wang, Zhen Kang, Ning Wang, Xian Lin, Yanli Yi, Xin Liu, Yunxiao Tian
• Journal: Pakistan journal of pharmaceutical sciences (Pak J Pharm Sci) Vol. 35 Issue 2(Special) Pg. 627-633 (Mar 2022) ISSN: 1011-601X [Print] Pakistan
• PMID: 35668563 (Publication Type: Journal Article)

Chemical References

• Protein Kinase Inhibitors
• Afatinib

Topics

• Afatinib (adverse effects)
• Antineoplastic Combined Chemotherapy Protocols (adverse effects)
• Carcinoma, Non-Small-Cell Lung (drug therapy)
• Humans
• Lung Neoplasms (drug therapy)
• Mutation
• Protein Kinase Inhibitors (therapeutic use)
• Retrospective Studies